Glaucoma

Austin, TX

13 Glaucoma Trials near Austin, TX

Power is an online platform that helps thousands of Glaucoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

100 Participants Needed

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

126 Participants Needed

This trial is testing a new medication called AGN-193408 SR to see if it can safely lower eye pressure in people with open-angle glaucoma or ocular hypertension.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

96 Participants Needed

This trial is evaluating the placement and effects of a tiny device called the Hydrus Microstent in patients having cataract surgery. The device helps drain fluid from the eye to reduce pressure. The study will monitor patients over time to see how well the device works and if there are any issues. The Hydrus Microstent is designed to increase fluid drainage from the eye and lower eye pressure.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:45+

545 Participants Needed

This trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

696 Participants Needed

This trial tests a long-lasting eye medication called Bimatoprost SR. It is for people with certain eye conditions who can't use regular eye drops effectively. The medication works by helping fluid drain from the eye, reducing pressure. Bimatoprost has been widely used for glaucoma management, typically delivered via eye drops, but newer methods like sustained-release implants are being explored to improve efficiency.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

515 Participants Needed

This trial tests a small device that releases medication inside the eye to help patients with high eye pressure due to glaucoma or ocular hypertension. The medication helps fluid drain from the eye, reducing pressure and preventing vision problems.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

105 Participants Needed

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

455 Participants Needed

This trial is testing a small device called the MINIject™ implant, which is designed to help lower eye pressure in people with primary open-angle glaucoma. The device works by making it easier for fluid to drain from the eye, reducing pressure and potentially preventing vision loss.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:46+

975 Participants Needed

This trial evaluates the safety and effectiveness of the ELIOS System, a procedure to lower eye pressure, in adults with mild to moderate primary open-angle glaucoma who are undergoing cataract surgery.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:45+

318 Participants Needed

Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 participants aged 45 years or older with open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United States. All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:45+

65 Participants Needed

A study of the Streamline Surgical System versus competitor
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22+

150 Participants Needed

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:22+

400 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

Know someone looking for new options? Spread the word